Gonorrhea treatment starts with the infection site, symptoms and any complications. Urogenital, throat and rectal infections do not share every treatment option.
Tell the chosen location whether you have a positive test, symptoms or a partner exposure. Confirm the capacity for examination, genital/throat/rectal sampling as appropriate and the medication or administration pathway. Bring the complete result and all allergies, medicines and pregnancy information. A newer oral treatment is suitable only for its labeled infection site and eligibility; the clinician may recommend ceftriaxone or another appropriate pathway. Ask how partners, persistent symptoms and retesting will be handled. Confirm actual drug supply, the appointment and plan approval before visiting.
Gonorrhea treatment starts with the infection site, symptoms and any complications. Urogenital, throat and rectal infections do not share every treatment option. Many people have no symptoms, so a partner’s diagnosis or screening result can still require care. New oral medicines add choices for eligible uncomplicated urogenital infection, while ceftriaxone remains the standard regimen in the current CDC guideline. Your plan should also cover other infections, partners and follow-up.
Antibiotics clear susceptible gonorrhea bacteria; they do not provide lasting immunity. Symptoms improving does not rule out infection at another site or prevent reinfection. Treatment selection takes account of resistance, drug allergy, pregnancy, infection location and the ability to complete the regimen. A medicine used for prevention, such as doxy-PEP, is not a substitute for gonorrhea treatment.
People with a positive result, a diagnosed partner exposure or compatible symptoms need clinical assessment. Tell the clinician about oral and anal exposures so throat and rectal infections are not missed. Blujepa’s gonorrhea label applies from age 12 and 45 kg, with limited or no alternatives; Nuzolvence applies from age 12 and 35 kg. Both approvals are for uncomplicated urogenital disease. A younger child, pregnancy, pelvic inflammatory disease, epididymitis or disseminated infection needs an appropriate separate pathway.
Bring the complete laboratory report rather than only a notification. The clinician reviews sampled sites, prior treatment and partner information and checks for complications.
Current CDC guidance uses ceftriaxone injection as standard treatment. The December 2025 oral approvals have product-specific eligibility and safety checks. Approval is not a reason to use an oral drug for an unlabeled site or ignore interactions.
If chlamydia has not been excluded, the clinician determines whether additional treatment is needed. HIV, syphilis and other testing may be appropriate. Discuss pregnancy prevention, vaccination and HIV prevention based on your situation.
Sex partners need evaluation and treatment. Avoid sex for seven days after treatment and until partners have been treated and symptoms have resolved. Get a written retesting and symptom-contact plan.
Bring medication allergies, the drugs and supplements you take, pregnancy possibility and previous antibiotic treatment. Tell the service if you cannot receive an injection, swallow tablets or return for follow-up. Those are useful planning issues, but they do not establish that a specific oral product is safe for you. Ask whether the prescribed medicine treats every positive site and what happens if another test becomes positive later.
Seek urgent assessment for fever with severe pelvic or abdominal pain, significant testicular pain, eye symptoms or a painful swollen joint. Persistent symptoms after treatment may reflect reinfection, another diagnosis or treatment failure and can require culture and susceptibility testing. Do not repeatedly treat yourself with leftover antibiotics. A severe allergic reaction needs emergency care.
CDC recommends test of cure 7–14 days after treatment for pharyngeal gonorrhea. Routine test of cure is not needed for uncomplicated urogenital or rectal infections treated with recommended regimens, but new-drug or other clinical circumstances may require a specific plan. Retesting about three months later looks for reinfection and serves a different purpose. Ask which test you need and when.
Confirm evaluation, site-specific testing, the medication and any administration charge. A single price for ‘gonorrhea care’ may omit the visit, lab, additional infection treatment or follow-up. Confirm the actual quote, supply and approval for the chosen regimen. If you have symptoms or a diagnosed exposure, request prompt evaluation and an available appropriate regimen while financial details are checked.
Nao Medical Jamaica: 90-18 Sutphin Blvd, Jamaica, NY 11435. Call +1-917-310-3371 to confirm the specific service, clinician and appointment before travelling.
Contact the clinic to confirm this service, the clinician and appointment preparation. General clinic hours may differ from service appointment times.
The current public clinic record lists 90-18 Sutphin Blvd, Jamaica, NY 11435. Confirm the requested service, clinician capability, appointment and any medication delivery at this exact site before traveling. A clinic address does not establish that it administers every treatment.
Ask the selected service for the next available appointment for gonorrhea evaluation and testing. Confirm whether booking or a walk-in visit is appropriate before traveling. Collection can occur before laboratory results are available. Treatment depends on the assessment and test plan; a possible HIV exposure within 72 hours needs urgent PEP evaluation. Bring identification, relevant prior results and the exposure or symptom timeline.
Bring medication allergies, the drugs and supplements you take, pregnancy possibility and previous antibiotic treatment. Tell the service if you cannot receive an injection, swallow tablets or return for follow-up. Those are useful planning issues, but they do not establish that a specific oral product is safe for you. Ask whether the prescribed medicine treats every positive site and what happens if another test becomes positive later.
Bring the complete laboratory report rather than only a notification. The clinician reviews sampled sites, prior treatment and partner information and checks for complications.
Current CDC guidance uses ceftriaxone injection as standard treatment. The December 2025 oral approvals have product-specific eligibility and safety checks. Approval is not a reason to use an oral drug for an unlabeled site or ignore interactions.
If chlamydia has not been excluded, the clinician determines whether additional treatment is needed. HIV, syphilis and other testing may be appropriate. Discuss pregnancy prevention, vaccination and HIV prevention based on your situation.
Sex partners need evaluation and treatment. Avoid sex for seven days after treatment and until partners have been treated and symptoms have resolved. Get a written retesting and symptom-contact plan.
Gonorrhea treatment starts with the infection site, symptoms and any complications. Urogenital, throat and rectal infections do not share every treatment option. Many people have no symptoms, so a partner’s diagnosis or screening result can still require care. New oral medicines add choices for eligible uncomplicated urogenital infection, while ceftriaxone remains the standard regimen in the current CDC guideline. Your plan should also cover other infections, partners and follow-up.
People with a positive result, a diagnosed partner exposure or compatible symptoms need clinical assessment. Tell the clinician about oral and anal exposures so throat and rectal infections are not missed. Blujepa’s gonorrhea label applies from age 12 and 45 kg, with limited or no alternatives; Nuzolvence applies from age 12 and 35 kg. Both approvals are for uncomplicated urogenital disease. A younger child, pregnancy, pelvic inflammatory disease, epididymitis or disseminated infection needs an appropriate separate pathway.
Bring the complete laboratory report rather than only a notification. The clinician reviews sampled sites, prior treatment and partner information and checks for complications.
Current CDC guidance uses ceftriaxone injection as standard treatment. The December 2025 oral approvals have product-specific eligibility and safety checks. Approval is not a reason to use an oral drug for an unlabeled site or ignore interactions.
If chlamydia has not been excluded, the clinician determines whether additional treatment is needed. HIV, syphilis and other testing may be appropriate. Discuss pregnancy prevention, vaccination and HIV prevention based on your situation.
Sex partners need evaluation and treatment. Avoid sex for seven days after treatment and until partners have been treated and symptoms have resolved. Get a written retesting and symptom-contact plan.
CDC recommends test of cure 7–14 days after treatment for pharyngeal gonorrhea. Routine test of cure is not needed for uncomplicated urogenital or rectal infections treated with recommended regimens, but new-drug or other clinical circumstances may require a specific plan. Retesting about three months later looks for reinfection and serves a different purpose. Ask which test you need and when.
Nuzolvence's US indication is uncomplicated urogenital gonorrhea in eligible patients. It is not an approved substitute for chlamydia or Mycoplasma genitalium treatment. If another infection is detected, the clinician chooses its separate regimen and follow-up. Do not assume one oral packet treats every positive STI site or organism.
Do not assume the medicine, laboratory work, administration, monitoring or follow-up is included in the evaluation fee. Ask for an itemized estimate and identify which charges go to the clinic, pharmacy or laboratory. An approved appointment benefit and an approved medication benefit can be separate decisions.
If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact Sharad Suri at service@naomedical.com or by phone at (917) 633-1548 Extension 288. In our goal to answer your questions as quick as possible, we use the assistance of a large language model wherever applicable. If there are any errors or concerns, please bring it to our attention by emailing us.
Enter your phone number to begin scheduling your appointment.
You will be redirected to complete the appointment booking. Next: Book Appointment
Nao Medical will never sell your information to a third party.
Choose urgent care for a non-emergency illness or minor injury. For preventive visits and ongoing management, explore primary care at this location.
Visiting later? Review after-hours options and confirm clinic hours before traveling. For a life-threatening emergency, call 911.
(917) 310-3371
Facebook
Instagram
Twitter
LinkedIn
